Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
It develops a proprietary gene editing platform based on CRISPR technology.
The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer.
It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders.
The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013.
Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 24 | -0.76 Decreased by -7.04% | -0.66 Decreased by -15.15% |
| Feb 28, 24 | -0.23 Increased by +73.86% | -0.54 Increased by +57.41% |
| Nov 3, 23 | -0.55 Increased by +32.10% | -0.57 Increased by +3.51% |
| Aug 2, 23 | -0.56 Increased by +28.21% | -0.76 Increased by +26.32% |
| May 5, 23 | -0.71 Increased by +4.05% | -0.78 Increased by +8.97% |
| Feb 22, 23 | -0.88 Decreased by -44.26% | -0.80 Decreased by -10.00% |
| Nov 2, 22 | -0.81 Decreased by -42.11% | -0.86 Increased by +5.81% |
| Aug 3, 22 | -0.78 Increased by +3.70% | -0.82 Increased by +4.88% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 5.34 M Increased by +12.60 K% | -45.02 M Increased by +16.53% | Decreased by -843.68% Increased by +99.34% |
| Jun 30, 23 | 2.89 M Decreased by -54.62% | -40.29 M Increased by +23.51% | Decreased by -1.40 K% Decreased by -68.56% |
| Mar 31, 23 | 9.85 M Increased by +45.49% | -45.57 M Increased by +9.37% | Decreased by -462.56% Increased by +37.71% |
| Dec 31, 22 | 6.54 M Decreased by -47.58% | -55.03 M Decreased by -32.82% | Decreased by -842.01% Decreased by -153.38% |
| Sep 30, 22 | 42.00 K Decreased by -99.32% | -53.93 M Decreased by -38.00% | Decreased by -128.41 K% Decreased by -20.26 K% |
| Jun 30, 22 | 6.36 M Increased by +1.58 K% | -52.67 M Increased by +4.68% | Decreased by -827.92% Increased by +94.32% |
| Mar 31, 22 | 6.77 M Increased by +4.19% | -50.28 M Increased by +11.37% | Decreased by -742.58% Increased by +14.93% |
| Dec 31, 21 | 12.47 M Increased by +9.20% | -41.44 M Increased by +33.70% | Decreased by -332.31% Increased by +39.28% |